Abstract: In the present invention, the proteomic identification of HBc interacting factors in the nucleus of human hepatocytes revealed a majority of RNA-binding proteins (RBPs) intervening in mRNA metabolism and especially, the serine/arginine-rich splicing factor (10) (SRSF1O) which was found enriched nearly (3000) times in HBc complexes. Inventors demonstrated that the inhibition of SRSF1O phosphorylation with the small molecule 1C8 (4-pyridinonebenzisothiazole carboxamide) induces a strong inhibition of HBV replication (genotypes C and D) in persistently-infected hepatocytes, as well as to a strong inhibition of the establishment of HBV cccDNA in de novo infection settings. Accordingly the present invention relates to an inhibitor of SRSF1O activity for use in the treatment of Hepatitis B virus (HBV) infection said inhibitor maintain SRSF1O in a dephosphorylated state and prevents or reduces the splicing activity of SRSF1O.

Abstract: The present invention relates to an isolated nucleic acid sequence comprising a first DNA sequence comprising a cis-acting replication element (CARE) from an Adeno-Associated Virus (AAV), and a second DNA sequence operably linked to said CARE, wherein amplification of said isolated nucleic acid sequence occurs when said isolated nucleic acid sequence is integrated in the genome of a cell and said cell is contacted with a CARE-dependent replication unducer (CARE-DRI). It also relates to amplification methods using a CARE-dependent replication inducer (CARE-DRI) and packaging cell-lines wherein replication of the integrated rep and cap genes is inducible by a CARE-DRI.

Abstract: The present invention relates to methods and compositions for the production of recombinant Adeno-Associated Viruses (rAAV). In particular, the invention discloses nucleic acid constructs and packaging cells having improved properties for rAAV production, as well as novel methods of titration and characterization of rAAV preparations. The invention also describes novel sequences which promote or increase the packaging of nucleic acids in rAAV, and their use for producing rAAV with high efficiency. The invention can be used for producing or testing high quality rAAV preparations, for biological, preclinical, clinical or pharmaceutical uses.

Abstract: The present invention relates to methods and compositions for the production of recombinant Adeno-Associated Viruses (rAAV). In particular, the invention discloses nucleic acid constructs and packaging cells having improved properties for rAAV production, as well as novel methods of titration and characterization of rAAV preparations. The invention also describes novel sequences which promote or increase the packaging of nucleic acids in rAAV, and their use for producing rAAV with high efficiency. The invention can be used for producing or testing high quality rAAV preparations, for biological, preclinical, clinical or pharmaceutical uses.